|
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma.
|
30828569 |
2019 |
|
Myasthenia Gravis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association of polymorphism in CTLA-4 gene with the clinical variables and severity of MG.
|
31473094 |
2019 |
|
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myasthenia gravis and encephalitis were associated with anti-PD-1 whereas other neurologic AEs were associated with anti-CTLA-4.
|
31118078 |
2019 |
|
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the correlations between CTLA-4 SNPs and MG susceptibility, a meta-analysis was performed following a series of database searching.
|
30009380 |
2018 |
|
Myasthenia Gravis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In conclusion, the results obtained from the present study highly indicated that CTLA-4 methylation might play a role in facilitating the occurrence of MG and increasing the expressions of related cytokines through the upregulation of AchR-Ab and E-Ach.
|
29718870 |
2018 |
|
Myasthenia Gravis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dysregulation of suppressive and migratory markers on Tregs have been linked to the pathogenesis of both MS and MG. For example, genetic abnormalities have been found in Treg suppressive markers CTLA-4 and CD25, while others have shown a decreased expression of FoxP3 and IL-10.
|
28599652 |
2017 |
|
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings highlight the role of auto-antigen gene (CHRNA1) in the autoimmune reactions against AChR and reveal synergistic contribution of genes of both auto-antigen and immune-regulating proteins (AIRE and CTLA-4) in the pathogenesis of MG.
|
27501803 |
2017 |
|
Myasthenia Gravis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In sharp contrast with TAMG, we now find that: i) CTLA4(low) +49G(+) genotypes were more frequent (p = 0.0029) among the 69 LOMG patients with age at onset ≥60 years compared with 172 healthy controls; ii) thymic export of naïve T cells from the non-neoplastic thymuses of 36 LOMG patients was lower (p = 0.0058) at diagnosis than in 77 age-matched controls.
|
24373506 |
2014 |
|
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evidence from Caucasians supported a genetic predisposition of CTLA4 to myasthenia gravis (MG), but the contribution in East Asians has not been established.
|
25003519 |
2014 |
|
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Many of the non-HLA genes, such as PTPN22 and CTLA-4, have been previously studied in MG and other autoimmune diseases and their association with MG has been reevaluated in more cohesive groups of patients.
|
24294607 |
2013 |
|
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
High levels of soluble cytotoxic T-lymphocyte antigen 4 (soluble CTLA-4), an alternative splice form of the regulatory T-cell (Treg) associated CTLA-4 gene, have been associated with type 1 diabetes (T1D) and other autoimmune diseases, such as Grave's disease and myasthenia gravis.
|
22218756 |
2012 |
|
Myasthenia Gravis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to analyze the only coding SNP CTLA-4 +49 A/G polymorphism in patients with either infectious (Chagas's, Dengue, and American cutaneous leishmaniasis) or autoimmune diseases (myasthenia gravis, pemphigus, and psoriasis).
|
19345707 |
2009 |
|
Myasthenia Gravis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
The two SNPs in the promoter region are associated with MG and might cause abnormal alternative splicing and affect the expression of CD152, thereby contributing to the pathogenesis of MG.
|
18088253 |
2008 |
|
Myasthenia Gravis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study reveals an abnormal spectrum of mRNA expression of CTLA-4 in MG patients, which marks the importance of studying gene expression of alternative splicing.
|
18595775 |
2008 |
|
Myasthenia Gravis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
This study reveals an abnormal spectrum of mRNA expression of CTLA-4 in MG patients, which marks the importance of studying gene expression of alternative splicing.
|
18595775 |
2008 |
|
Myasthenia Gravis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The two SNPs in the promoter region are associated with MG and might cause abnormal alternative splicing and affect the expression of CD152, thereby contributing to the pathogenesis of MG.
|
18088253 |
2008 |
|
Myasthenia Gravis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Taking the association of a gain-of-function polymorphism of the CTLA-4 and PTPN22 gene with MG in thymomas into account, we conclude that these acquired cellular abnormalities of the thymoma microenvironment in concert with inherited genetic high-risk polymorphisms of immunoregulatory genes have an impact on intratumorous thymopoiesis and appear to tip the balance toward central tolerance failure and development of MG.
|
18567864 |
2008 |
|
Myasthenia Gravis
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
The unusual disease association with a CTLA4high genotype implies a unique pathogenesis of paraneoplastic MG, with high CTLA4 levels possibly supporting the nontolerogenic selection of CD4+ T cells in MG-associated thymomas.
|
16178018 |
2005 |
|
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, our results suggest that the suppression of myasthenia gravis-associated T cell responses exerted by the dual APL is mediated by the CD4+CD25+ immunoregulatory T cell function via TGF-beta or cytotoxic T lymphocyte-associated antigen 4, which further stimulate a cascade of events that up-regulates apoptosis.
|
15677327 |
2005 |
|
Myasthenia Gravis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The unusual disease association with a CTLA4high genotype implies a unique pathogenesis of paraneoplastic MG, with high CTLA4 levels possibly supporting the nontolerogenic selection of CD4+ T cells in MG-associated thymomas.
|
16178018 |
2005 |
|
Myasthenia Gravis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis.
|
11857062 |
2002 |
|
Myasthenia Gravis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence.
|
12225905 |
2002 |
|
Myasthenia Gravis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we have performed genotyping for CTLA4 polymorphisms, and investigated expression by peripheral blood mononuclear cells of CTLA-4 mRNA and protein, in patients with MS and myasthenia gravis and in healthy controls.
|
11426323 |
2001 |
|
Myasthenia Gravis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The current results point to the (AT)n in Ctla-4 as a myasthenia gravis facilitating mutation under certain permissive environments by influencing the T cell reactivity via the CD28 pathway.
|
10713366 |
2000 |
|
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic association of Ctla-4 to myasthenia gravis with thymoma.
|
9688341 |
1998 |